ArticleBMC cancer2025
Reticulocalbin-1 in clear cell renal cell carcinoma: clinical and functional evidence for its role as a biomarker and potential therapeutic target.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear-cell renal cell carcinoma (ccRCC) is the most prevalent subtype of renal cell carcinoma, and its prognosis in a metastatic stage is poor. Although therapeutic options are continuously improving, better combination therapies and individualized approaches are still needed. Reticulocalbin-1 (RCN1), located in the endoplasmic reticulum (ER), is associated with aggressiveness and poor prognosis in many solid tumors, but its role in ccRCC has not been analyzed before.
methodsIn this study, we performed in-silico transcriptomic data mining to analyze RCN1 expression at mRNA and protein levels using large publicly available databases and conducted the first large-scale cohort study on the impact of RCN1 in ccRCC, including data from 306 patients who underwent tumor resection at the Clinic of Urology, University Hospital Bonn. We examined the correlation of RCN1 expression with clinicopathological parameters and overall survival. Additionally, we analyzed the association of RCN1 expression with CD8 T-lymphocyte and macrophage infiltration. In vitro functional analysis was performed by silencing RCN1 using siRNA in Caki-1 and A498 cell lines to determine its role in tumor cell behavior.
resultsRCN1 is highly expressed in ccRCC at both the mRNA and protein levels in public databases, which was confirmed by our cohort data, where RCN1 was found to be highly and homogenously expressed in 63.7% of ccRCCs. High RCN1 expression was associated with shorter overall survival both at the mRNA (p < 0.001) and protein levels (p = 0.01). Furthermore, high RCN1 expression was correlated with higher tumor grade (p = 0.002), tumor stage (p = 0.036), presence of lymph node metastases (p = 0.004), and distant metastases (p = 0.017). Clusters of macrophages tended to correlate with RCN1 expression (p = 0.051), but no significant correlation was found between RCN1 expression and the amount of CD8 T-lymphocytes. Additionally, silencing RCN1 led to a significant reduction in tumor cell migration and invasion.
conclusionOur results confirm that RCN1 is highly and homogenously expressed in ccRCC and correlates with poor prognosis and unfavorable clinicopathological parameters. RCN1 could serve as a reliable biomarker for prognosis in ccRCC and shows potential as a target for therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.